CELL-SELEX: Novel Perspectives of Aptamer-Based Therapeutics

Aptamers, single stranded DNA or RNA molecules, generated by a method called SELEX (systematic evolution of ligands by exponential enrichment) have been widely used in various biomedical applications. The newly developed Cell-SELEX (cell based-SELEX) targeting whole living cells has raised great expectations for cancer biology, -therapy and regenerative medicine. Combining nanobiotechnology with aptamers, this technology opens the way to more sophisticated applications in molecular diagnosis. This paper gives a review of recent developments in SELEX technologies and new applications of aptamers.

[1]  C D Claussen,et al.  Aptamer-based isolation and subsequent imaging of mesenchymal stem cells in ischemic myocard by magnetic resonance imaging. , 2007, RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin.

[2]  C. Férec,et al.  The potential of oligonucleotides for therapeutic applications. , 2006, Trends in biotechnology.

[3]  C. Thompson,et al.  Apoptosis in the pathogenesis and treatment of disease , 1995, Science.

[4]  L. Gold,et al.  The use of aptamers in large arrays for molecular diagnostics. , 1999, Molecular diagnosis : a journal devoted to the understanding of human disease through the clinical application of molecular biology.

[5]  Igor Belyaev,et al.  Targeting Ku protein for sensitizing of breast cancer cells to DNA-damage. , 2004, International journal of molecular medicine.

[6]  Gerhard Ziemer,et al.  A New Technique for the Isolation and Surface Immobilization of Mesenchymal Stem Cells from Whole Bone Marrow Using High‐Specific DNA Aptamers , 2006, Stem cells.

[7]  Bernd Groner,et al.  The interaction of specific peptide aptamers with the DNA binding domain and the dimerization domain of the transcription factor Stat3 inhibits transactivation and induces apoptosis in tumor cells. , 2004, Molecular cancer research : MCR.

[8]  Andrew D. Ellington,et al.  Aptamer mediated siRNA delivery , 2006, Nucleic acids research.

[9]  Omid C. Farokhzad,et al.  Nanoparticle-Aptamer Bioconjugates , 2004, Cancer Research.

[10]  Judy Lieberman,et al.  Interfering with disease: a progress report on siRNA-based therapeutics , 2007, Nature Reviews Drug Discovery.

[11]  Ali Khademhosseini,et al.  Applications in Drug Delivery and Tissue Engineering , 2006 .

[12]  H. Horvitz,et al.  NOBEL LECTURE: Worms, Life and Death , 2003, Bioscience reports.

[13]  Joshua E. Smith,et al.  Aptamer-conjugated nanoparticles for the collection and detection of multiple cancer cells. , 2007, Analytical chemistry.

[14]  Kemin Wang,et al.  Selection of aptamers for molecular recognition and characterization of cancer cells. , 2007, Analytical chemistry.

[15]  Weihong Tan,et al.  Optimization and Modifications of Aptamers Selected from Live Cancer Cell Lines , 2007, Chembiochem : a European journal of chemical biology.

[16]  Bertrand Tavitian,et al.  Neutralizing Aptamers from Whole-Cell SELEX Inhibit the RET Receptor Tyrosine Kinase , 2005, PLoS biology.

[17]  M. Djordjevic.  SELEX experiments: new prospects, applications and data analysis in inferring regulatory pathways. , 2007, Biomolecular engineering.

[18]  George Quick,et al.  Antidote-mediated control of an anticoagulant aptamer in vivo , 2004, Nature Biotechnology.

[19]  Yong Wang,et al.  Cell type–specific delivery of siRNAs with aptamer-siRNA chimeras , 2006, Nature Biotechnology.

[20]  Weihong Tan,et al.  Aptamer-conjugated nanoparticles for selective collection and detection of cancer cells. , 2006, Analytical chemistry.

[21]  L. Gold,et al.  Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. , 1990, Science.

[22]  J. Szostak,et al.  In vitro selection of RNA molecules that bind specific ligands , 1990, Nature.

[23]  Jean-Michel Foidart,et al.  Pegaptanib and age-related macular degeneration. , 2005, The New England journal of medicine.

[24]  Markus Kurz,et al.  Conjugation to polyethylene glycol polymer promotes aptamer biodistribution to healthy and inflamed tissues. , 2005, Oligonucleotides.

[25]  Petra Burgstaller,et al.  Aptamers as tools for target prioritization and lead identification. , 2002, Drug discovery today.

[26]  L. Kèlland,et al.  Discovery and development of anticancer aptamers , 2006, Molecular Cancer Therapeutics.

[27]  Ariel D. Anbar,et al.  Aptamers Evolved from Cultured Cancer Cells Reveal Molecular Differences of Cancer Cells in Patient Samples , 2007 .

[28]  Chih-Ching Huang,et al.  Aptamer-functionalized gold nanoparticles for turn-on light switch detection of platelet-derived growth factor. , 2007, Analytical chemistry.

[29]  D. Shangguan,et al.  Aptamers evolved from live cells as effective molecular probes for cancer study , 2006, Proceedings of the National Academy of Sciences.

[30]  M. Strano,et al.  Aptamer-capped nanocrystal quantum dots: a new method for label-free protein detection. , 2006, Journal of the American Chemical Society.

[31]  J. Szostak,et al.  Selection in vitro of single-stranded DNA molecules that fold into specific ligand-binding structures , 1992, Nature.

[32]  Nieng Yan,et al.  RNA Aptamers Targeting the Cell Death Inhibitor CED-9 Induce Cell Killing in Caenorhabditis elegans* , 2006, Journal of Biological Chemistry.

[33]  Allen C Ho,et al.  Pegaptanib for choroidal neovascularization in treatment-naïve exudative age-related macular degeneration. , 2007, Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye.

[34]  S. Jayasena.  Aptamers: an emerging class of molecules that rival antibodies in diagnostics. , 1999, Clinical chemistry.

[35]  Ying-Fon Chang,et al.  Tumor targeting by an aptamer. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[36]  S. Mukaratirwa,et al.  Tenascin expression in relation to stromal tumour cells in canine gastrointestinal epithelial tumours. , 2003, Journal of comparative pathology.

[37]  L. Gold,et al.  A tenascin-C aptamer identified by tumor cell SELEX: Systematic evolution of ligands by exponential enrichment , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[38]  W. Pierce,et al.  AS1411 alters the localization of a complex containing protein arginine methyltransferase 5 and nucleolin. , 2007, Cancer research.

[39]  D. Drolet,et al.  Aptamer affinity chromatography: combinatorial chemistry applied to protein purification. , 1999, Journal of chromatography. B, Biomedical sciences and applications.

[40]  L S Green,et al.  Aptamers as reagents for high-throughput screening. , 2001, BioTechniques.

[41]  Robert Langer,et al.  Nanoparticle–aptamer bioconjugates for cancer targeting , 2006, Expert opinion on drug delivery.

[42]  L. Gold,et al.  High affinity ligands from in vitro selection: complex targets. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[43]  George A. Williams,et al.  TREATMENT OF NAÏVE LESIONS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH PEGAPTANIB , 2007, Retina.

[44]  Gerhard Ziemer,et al.  The effect of electrochemical functionalization of Ti-alloy surfaces by aptamer-based capture molecules on cell adhesion. , 2007, Biomaterials.

[45]  M. Mascini,et al.  Analytical applications of aptamers. , 2005, Biosensors & bioelectronics.

[46]  V Heinemann,et al.  A phase II pilot trial with RP101 in advanced pancreatic carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  D. Guyer,et al.  Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease , 2006, Nature Reviews Drug Discovery.

[48]  Jeong-O Lee,et al.  Aptamers as molecular recognition elements for electrical nanobiosensors , 2007, Analytical and bioanalytical chemistry.

[49]  B. Sullenger,et al.  The potential of aptamers as anticoagulants. , 2005, Trends in cardiovascular medicine.

[50]  Xin Sheng Zhao,et al.  Aptamer biosensor for protein detection using gold nanoparticles. , 2008, Analytical biochemistry.

[51]  Ali Khademhosseini,et al.  Nanobiotechnology drug deliery and tissue engineering drug delivery and tissue engineering , 2006 .

[52]  François Natt,et al.  siRNAs in drug discovery: target validation and beyond. , 2007, Current opinion in molecular therapeutics.

[53]  Bernd Groner,et al.  Sequence-specific Peptide Aptamers, Interacting with the Intracellular Domain of the Epidermal Growth Factor Receptor, Interfere with Stat3 Activation and Inhibit the Growth of Tumor Cells* , 2003, Journal of Biological Chemistry.

[54]  B. Sullenger,et al.  Aptamers: an emerging class of therapeutics. , 2005, Annual review of medicine.